Odanacatib (MK-0822), a potent, orally-active inhibitor of cathepsin K, is under clinical development for treatment of postmenopausal osteoporosis. This poster describes base model development of a semi-mechanistic model of bone turnover to describe creatinine adjusted urinary aminoterminal crosslinked telopeptides of Type I collagen (uNTx), a bone resorption biomarker, and lumbar spine and distal forearm bone mineral density (LS- and DF-BMD) data from a Phase IIb dose-ranging study during and after treatment with odanacatib.
Population Approach Group in Europe (PAGE), Athens, Greece, June 2011
By Stefan Zajic, Julie A. Stone, David Jaworowicz, Albert Leung, Le Thi Duong, Julie Passarell, Jill Fiedler-Kelly, Dosinda Cohn, Nadia Verbruggen, and Aubrey Stoch